Items where authors include "Lindgren, P."

Article

Landmesser, U., Lindgren, P., Hagström, E. et al. (7 more authors) (2022) Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal - Quality of Care and Clinical Outcomes, 8 (1). pp. 31-38. ISSN 2058-5225

Fonarow, G.C., van Hout, B. orcid.org/0000-0001-9698-6094, Villa, G. et al. (2 more authors) (2019) Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiology, 4 (7). pp. 691-695. ISSN 2380-6583

Fonarow, G.C., Keech, A.C., Pedersen, T.R. et al. (8 more authors) (2017) Cost-effectiveness of Evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiology, 2 (10). pp. 1069-1078. ISSN 2380-6583

Villa, G., Lothgren, M., Kutikova, L. et al. (7 more authors) (2017) Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical Therapeutics, 39 (4). pp. 771-786. ISSN 0149-2918

Gandra, S.R., Villa, G., Fonarow, G.C. et al. (4 more authors) (2016) Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39 (6). pp. 313-320. ISSN 0160-9289